M.R.L.41 in the treatment of secondary amenorrhoea and endometrial hyperplasia

Charles D

doi:10.1016/s0140-6736(62)90178-2

Lancet (London, England), 2(7250), 278-280, 1962

M.R.L.41 in the treatment of secondary amenorrhoea and endometrial hyperplasia

D CHARLES

Author affiliations

Western Infirmary ROR

DOI10.1016/s0140-6736(62)90178-2 PMID13878270

Read at publisher

Abstract

No abstract available for this article.

Topics

Reproductive Endocrinology > Progestogens > Treatment of Amenorrhea General OB/GYN > Endometrial Hyperplasia > Progestational Therapy Menstrual Cycle > Amenorrhea > Hormonal Treatment

MRL 41 treatment secondary amenorrhoea, progestational agent endometrial hyperplasia treatment, secondary amenorrhea progestogen therapy 1960s, Charles D MRL-41 amenorrhea endometrial hyperplasia, synthetic progestogen withdrawal bleeding amenorrhea, endometrial hyperplasia progestational steroid treatment, hormonal therapy secondary amenorrhea historical, progestogen induced withdrawal bleed endometrial assessment, pharmacological treatment absent menstruation progestogen, endometrial proliferation progestin therapy

PMID 13878270 13878270 DOI 10.1016/s0140-6736(62)90178-2 10.1016/s0140-6736(62)90178-2

Cite this article

Charles, D. (1962). M.R.L.41 in the treatment of secondary amenorrhoea and endometrial hyperplasia. *Lancet (London, England)*, *2*(7250), 278-280. https://doi.org/10.1016/s0140-6736(62)90178-2

Keywords

Amenorrhea/therapy, Disease, Endometrial Hyperplasia, Endometrium, Female, Humans, Stilbenes/therapy, Stilbenes, AMENORRHEA/therapy, ENDOMETRIUM/diseases, STILBENES/therapy

M.R.L.41 in the treatment of secondary amenorrhoea and endometrial hyperplasia

Abstract

Topics

Cite this article

Keywords

Related articles

Disease burden attributable to intimate partner violence against females and sexual violence against children in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023

Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023

Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023

Informing women with endometriosis about ovarian cancer risk